Literature DB >> 18594904

Sentinel node detection in patients with thyroid carcinoma: a meta-analysis.

P G H M Raijmakers1, M A Paul, P Lips.   

Abstract

OBJECTIVE: This study was designed to review the diagnostic performance of sentinel node (SN) detection for assessment of the nodal status in thyroid carcinoma patients and to determine the technique (using blue dye or Technetium-99m colloid (99mTc) that demonstrated the highest success rate with regard to the detection rate and sensitivity.
METHODS: A comprehensive computer literature search of studies published in English language through December 2007 and regarding SN procedures in patients with thyroid disorders was performed in MEDLINE. Pooled values regarding the SN detection rate and the pooled sensitivity values of the SN procedure were presented with a 95% confidence interval (CI) for the different SN detection techniques.
RESULTS: Ultimately, we identified 14 studies comprising a total of 457 patients. Of these, ten studies (n = 329 patients) used the blue dye technique with a pooled SN detection of 83% (95% CI, 79-87%). The remaining four studies (n = 128) used 99mTc-colloid with a pooled SN detection of 96% (95% CI, 91-99%; p < 0.05 vs. blue dye technique).
CONCLUSION: In patients with suspected thyroid carcinoma, SN biopsy demonstrated a higher SN detection rate when 99mTc was used (96%) instead of the blue dye technique (83%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594904      PMCID: PMC2517092          DOI: 10.1007/s00268-008-9657-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


Introduction

Lymph node involvement is commonly detected in patients with thyroid cancer, reportedly up to 70% [1-3]. Furthermore, cervical lymph node metastases are a frequent cause of recurrent thyroid cancer [4]. However, the prognostic importance and role of elective lymphadenectomy in thyroid cancer is controversial. Nodal metastases are a significant risk factor for survival in patients with thyroid cancer [3]. Because this risk varies considerably between different age groups, the prognostic importance and role of elective lymphadenectomy are controversial. Hence, knowledge regarding the presence or absence of lymphatic metastases may be of interest in the staging procedure of patients with thyroid cancer. Systematic lymphadenectomy is a standard technique, which is currently used to detect lymphatic metastatic spread. Alternative techniques, including resection of macroscopic enlarged nodes, also are used. Heterogeneity with regard to removal of the lymph nodes may introduce bias during the staging of thyroid patients, thereby affecting the predictive value of staging classification procedures, including the presence of lymphatic metastatic spread. Furthermore, this heterogeneity in the lymph node removal may explain the controversy regarding the optimal procedure. Certain institutions perform routine lymph node dissection, whereas others refrain from routine dissection. Recent studies suggested the use of sentinel node (SN) detection as a less invasive method for studying the lymphatic metastatic spread in patients with breast cancer, melanoma, cervical cancer, and thyroid carcinoma [5-8]. However, considerable variation has been reported between studies with regard to the success rates of these SN procedures in patients with thyroid cancer; for example, Dixon et al. reported SN detection in merely 65% of the patients, whereas others have reported 100% detection rates [9, 10]. In a recently concluded meta-analysis regarding SN detection in patients with cervical cancer, we observed that the use of radiotracers vs. the blue dye technique was an important factor that determined the success rate of SN detection [11]. This review and meta-analysis was designed to determine whether sentinel lymph nodes (SLNs) can be identified accurately in patients with thyroid cancer with the injection of a radiotracer or a blue dye. Furthermore, we studied the effect of different detection techniques on the SN detection rate in these patients.

Methods

Study selection

A comprehensive computer literature search of studies published in English language and comprising human subjects was performed to identify articles related to the diagnostic performance of SN and thyroid carcinoma when compared with histopathological findings used as the reference standard. MEDLINE database through December 2007 was searched for the following terms: “thyroid neoplasm”; “sentinel” as the medical subject headings (MeSH). The list of articles was supplemented by cross-checking the reference lists containing the identified articles. Review articles, letters, comments, conference proceedings, unpublished data, and case reports were excluded from this review. We included studies that reported SN detection using the blue dye technique or a radiotracer in patients with suspected thyroid carcinoma. We used the above-mentioned inclusion and exclusion criteria [12, 13]. In short, only those studies that satisfied all of the following criteria were included: 1) minimum sample size of ten included patients; 2) the use of a radioactive tracer and/or blue dye during the SN procedure; 3) presence of “gold standard,” which was defined by the use of histopathological evaluation of surgically resected specimens, for sensitivity analysis; and 4) sufficient data to reassess sensitivity (number of true positives and false negatives) or the SN detection rate. The exclusion criterion was an overlap in the patient data (duplicate publication). In such cases, the more recent article with most patients was included with an adequate description of the study population.

Data analyses

The sensitivity of the SN procedure was determined from the number of true-positive (TP) and false-negative (FN) results obtained from individual studies. Studies that did not present patients with tumor-positive SNs were excluded from statistical pooling for the sensitivity analyses. However, these studies were included for pooling of the SN detection rate. Heterogeneities in the sensitivity and SN detection rate were tested by using the χ2 test. Additionally, we performed subgroup analysis for the different SN detection techniques: one group comprised studies that used 99mTc-colloid, and another group comprised studies that used the blue dye technique for SN detection. In the event of persisting heterogeneity between studies despite the subgroup analysis, we used the random effect model for statistical pooling of the data; on the other hand, a fixed effect model was implemented in the event of homogeneity. Pooled data are presented with 95% confidence intervals (CI). Finally, a Z-test was used to compare the pooled estimates of the values of sensitivity and SN detection rate obtained from the different SN detection techniques (blue dye or 99mTc-colloid). P < 0.05 was considered significant.

Results

Fourteen studies regarding SN were included to assess the SN detection rate in patients with a suspected thyroid carcinoma [9, 10, 14–25]. The present review comprised a total of 457 patients (Table 1). An intratumoral injection technique was used in the majority of the studies (10 of 14 studies), whereas a peritumoral injection technique was used in only four studies (Table 2).
Table 1

Patient characteristics of the studies included for the present meta-analysis

StudyYear n Male/female ratioMean age (yr) [range] Thyroid nodule (% malignant)Mean tumor size (cm) [range]
Dixon et al. [9]2000405/3542 [25–75] 33[1–3.5]
Kelemen et al. [18]1998173/1448 [22–68] 712 [0.8–4]
Haigh and Giuliano [19]20003845
Arch-Ferrer et al. [20]2001222/20371002.5
Takami et al. [21]2003688/6042 [22–69]1001.9 [0.6–3.9]
Tsugawa et al. [22]2001388/3048 [24–72]1001.3 [0.5–2.8 ]
Pelizzo et al. [16]2001298/2144 [21–86]1001.8 [0.5–4]
Chow et al. [23]2004153/1254 median [26–71]100
Fukui et al. [24]2001223/19531001.3
Dzodic et al. [15]20064010/3042 [23–57]1001.5 [median]
Sahin et al. [25]200113[30–49]39
Stoeckli et al. [10]2003102/850 [20–74]67
Pelizzo et al. [17]20064112/2940 [21–68]981.24 [0.5–3 ]
Carcoforo et al. [14]2007647/5750 920.87
Table 2

Methodology used in the studies included for the present meta-analysis

Study (year) n Tracer usedTracer volume and doseInjection siteImaging SNHistopathologyMethod of surgery
Dixon et al. [9] (2000) 40Isosulfan blue dye0,18 ml (Max. 0.7 ml)IntratumoralFrozen sectionCentral or lateral modified lymph node (lnn) dissection (clinical indication)
Kelemen et al. [18] (1998) 17Isosulfan blue dye 0.5 ml (0.1–0.8 ml)IntratumoralFrozen biopsy, standard HE technique, and IHC cytokeratinTotal thyroidectomy (n = 16), lobectomy (n = 1) Central lymph node dissection (n = 3, positive sn)
Haigh and Giuliano [19] (2000) 38Isosulfan blue dye0.5–1.0 mlIntratumoralHE (2 sections) IHC cytokeratin (2 additional sections, in case of negative HE)Thyroidectomy
Arch-Ferrer et al. [20] (2001)22Isosulfan blue dye0.5 mlIntratumoralHE, IHC-cytokeratin-7 only on HE negative SNTotal thyroidectomy Dissection lymph nodes ipsilateral central compartment
Takami et al. [21] (2003) 68Isosulfan blue dye0.3 ml4 quadrant injectionHE stainingSubtotal thyroidectomy & central and modified ipsilateral lnn dissection (routine)
Tsugawa et al. [22] (2002) 38Patent blue dye0.2–0.5 mlIntratumoralHELobectomy and isthmusectomy (n = 28)
Total thyroidectomy (n = 10)
Modified radical neck dissection, ipsilateral (n = 28)
Modified radical neck dissection, bilateral (n = 8)
Pelizzo et al. [16] (2001)29Patent blue dye V (0.5%)0.25 ml per cm tumor sizeIntratumoralSnap-frozen samplingTotal thyroidectomy
Laterocervical lnn dissection (in case positive SN)
Chow et al. [23] (2004)15Patent blue dye V (2.5%)0.5–1.0 mlIntratumoralRoutineTotal thyroidectomy (n = 8)
Hemithyroidectomy (n = 7)
Central compartment lymphadenectomy (n = 15)
Fukui et al. [24] (2001)22Methylene blue dye0.1 ml 4 quadrant Peritumoral0.2 mm sections, HE, IHC on all nodesSubtotal thyroidectomy (n = 22)
Modified radical neck dissection (n = 22)
Dzodic et al. [15] (2006)40Methylene blue dye0.2 mlPeritumoralHE, IHC only on SNTotal thyroidectomy (n = 40),Node dissection central compartment (n = 40),SN biopsy (n = 37),Modified radical neck dissection (n = 9, positive node intraoperative)
Sahin et al. [25] (2001) 13 99mTc colloid0.2 ml 15 MBqIntratumoralDynamic and static imagingFrozen section, IHC only on SNND
Stoeckli et al. [10] (2002) 10 99mTc sulfur colloid 0.2 ml20 MBqIntratumorala Dynamic and static imagingSerial sectioning, HE and cytokeratin stainingSN resection, hemithyroidectomy
No neck lnn dissection
Pelizzo et al. [17] (2006) 41 99mTc nanocolloid0.1–0.2 ml 6 MBqIntratumoralDynamic and static imagingAt least one section, HE IHC on all nodesThyroid surgery, SN resection (nodes >10% activity of the hottest lymph node) Lymphadenectomy of involved compartment of metastasis positive SN (intraoperative)
Carcoforo et al. [14] (2007)64 99mTc nanocolloid0.3 ml 120 MBqPeritumoral (ultrasound guided) StaticHE Total thyroidectomy
Probe guided SN detection
Lymphadenectomy guided by inspection’/palpation

aChange protocol, initial start with peritumoral injection and later intratumoral injection

ND not described, HE hematoxylin and eosin staining, IHC immunohistochemistry

Patient characteristics of the studies included for the present meta-analysis Methodology used in the studies included for the present meta-analysis aChange protocol, initial start with peritumoral injection and later intratumoral injection ND not described, HE hematoxylin and eosin staining, IHC immunohistochemistry There was considerable variance in the histopathological procedure among the studies included for the analyses. For example, eight studies mentioned the use of an immunohistochemistry (IHC) technique for lymph node evaluation. Of these, two studies implemented the IHC technique in the SN only, whereas the remaining studies implemented IHC in all the lymph nodes. Furthermore, only two studies described the number of sections or slice thickness prepared during the histopathological analysis. Based on the technique used for SN detection, the studies were divided into the following two groups: four studies (n = 128 patients) used the 99mTc-colloid technique; and ten studies (n = 329 patients) used the blue dye technique for the purpose of SN detection. The pooled SN detection rate for studies using blue dye was 0.83 (95% CI, 0.79–0.87) and it was 0.96 (95% CI, 0.91–0.99; p < 0.05) for studies using the 99mTc-colloid (Fig. 1). Hence, the difference of detection rates was reaching a significant level and there was no overlap of the confidence intervals. Pooling of the sensitivity was performed for a total of six studies, which used the blue dye technique for SN detection; the pooled sensitivity was 0.873 (95% CI, 0.79–0.93). Accordingly, the false-negative rate was 12.7%. One of the four studies using 99mTc-colloid reported a false-negative rate of 11.3%.
Fig. 1

Plot of individual study values and pooled estimates of SN detection, including 95% confidence intervals

Plot of individual study values and pooled estimates of SN detection, including 95% confidence intervals

Discussion

The results of this meta-analysis indicate that studies using the technetium-labeled colloid (99mTc-colloid) technique yielded an approximately 13% higher SN detection rate compared with those using the blue dye technique for SN detection. Hence, detection of SNs in patients with suspected thyroid carcinoma using a technetium-labeled colloid may be more effective compared with that obtained with the use of the blue dye technique. There are little data regarding the false-negative rate (FNR) for SN detection with the use of 99mTc-colloid, only one study reported a FNR of 11.3% [14]. In contrast, the FNR for SN detection with the use of the blue dye technique was 12.7%. There was no meta-analysis possible of studies that used a combined technique of both blue dye and 99mTc-colloid. Presently, the surgical options for patients with thyroid carcinoma include total thyroidectomy or unilateral lobectomy. In addition, lymph node sampling may include no sampling, blind sampling, node picking of enlarged lymph nodes, and lymph node dissection. Obviously, differences in the surgical approaches may result in heterogeneity in the tumor classification. SN biopsy is a minimally invasive approach, and it offers a more standardized technique of lymph node assessment. Greater standardization in the evaluation technique renders more robustness to the prognostic value of lymph node metastasis in thyroid cancer patients. Furthermore, it may prompt a change in therapy in certain cases. For example, in institutions using unilateral lobectomy for the surgical treatment of small papillary thyroid carcinomas, the SN technique may offer additional prognostic value. Using the SN technique, it is possible to identify patients with lymph node metastasis. These patients with small carcinomas and SN metastasis may require total thyroidectomy followed by postoperative 131-iodide therapy (I-131 therapy) instead of unilateral lobectomy without any further treatment. SN evaluation also might result in an alteration in the tumor staging of certain patients. Especially, introduction of the IHC technique for detection of tumor cells in the SNs might increase the number of patients with lymph node metastases. With the use of IHC, it is now possible to detect micrometastases, which would have remained undetected earlier [26]; thus, a more accurate evaluation regarding the nodal status can be performed. The detection of micrometastases using SNs may enable selection of patients for further surgery or I-131 therapy; however, it remains to be seen whether additional treatment, such as I-131, would improve survival in patients with single SN micrometastasis. More importantly, lymph node metastasis is not uncommon in patients with small thyroid carcinomas. Noguchi et al. [3] observed that 69% of the patients with thyroid lesions measuring <1 cm demonstrated nodal metastasis. Prospective studies are required to resolve the issue regarding the optimal treatment for patients with small papillary thyroid carcinoma and lymph node metastasis. To facilitate a better prediction regarding the outcome for patients with thyroid cancer, several tumor staging classifications have been proposed. Furthermore, an accurate staging permits optimal stratification for new clinical studies. The National Thyroid Cancer Treatment Cooperative Study (NTCTCS) staging classification registration of 1,607 patients was prospectively validated and showed relatively high accuracy in predicting the outcome of patients with thyroid cancer [27]. According to this staging classification, cervical lymph node metastases are of importance in classifying patients. Patients older than aged 45 years with cervical lymph node metastases were classified as stage III (high risk), whereas those younger than aged 45 years and demonstrating cervical lymph node metastases were considered as stage I (low risk) [27]. There are potential advantages of the SN technique, for example, reduced morbidity compared with elective lymph node dissection. Furthermore, it offers a standardized technique of lymph node evaluation. Although we reviewed a limited number of studies with a total of 457 patients, it seems that the use of 99mTc-colloid enabled identification of SN in an additional 13% of the patients compared with those identified with the blue dye technique. Hence, for institutions considering the application of SN detection in patients with thyroid carcinoma, the use of 99mTc-colloid for SN detection offers a potentially higher success rate in identifying SN. The use of blue dye technique for SN detection may be less successful due to transport of the blue dye to the parathyroid glands. Considering the results of earlier techniques of SN detection in patients with melanoma and breast cancer, the combination of blue dye and 99mTc-colloid might be a superior alternative. Indeed, Catarci et al. [28] successfully performed SN detection in all six patients using a combination of 99mTc-colloid and blue dye. However, more and larger studies are necessary to assess the potential of the dual tracer approach in increased SN detection. Because we did not find any additional evidence regarding this method in the present literature, we could not perform a meta-analysis of this method. Meta-analysis has certain limitations, and publication bias is a potential confounder. SN studies with negative results (low detection rates or high FNRs may have a lower publication rate compared with those with clearly positive results). Furthermore, the methodological quality varies amongst studies. For example, only 7 of the 14 studies that were included in this meta-analysis have reported FNR data. Future studies reporting SN detection in patients with thyroid cancer should include FNR data in their results. The FNR is the single most important quality item for the SN technique. High numbers of false-negative SN renders the specific technique unsuitable for routine practice. Indeed, the pooled value of the FNR of six studies that used blue dye is higher compared with those that included patients with breast cancer or melanoma. Hence, further improvements in the SN technique for patients with thyroid carcinoma should be considered before a routine application is established. Future studies should investigate demographic data and data regarding the tumor size should be included to study any potential population differences. Finally, future studies should carefully report the histopathological methods used. It is relatively simple to obtain these data, such as the number of sections through the SN; however, they are lacking in the majority of the studies.

Conclusions

Our findings indicate that SN detection is possible in patients with thyroid cancer. The use of 99mTc-colloid enables SN identification in 96% of the patients. However, the use of blue dye technique is probably associated with a lower SN detection rate compared with that obtained by the 99mTc-colloid technique. The theoretical advantages of the SN technique require further probing through clinical studies. Furthermore, more studies are required to identify the optimal SN detection technique, especially with regard to the FNR. Additionally, the clinical impact of SN detection with regard to the prognosis and treatment requires further attention in new clinical studies.
  26 in total

1.  The value of contrast and subtraction arthrography in the assessment of aseptic loosening of total hip prostheses: a meta-analysis.

Authors:  Olivier P P Temmerman; Ide C Heyligers; Gerrit J J Teule; Otto S Hoekstra; Pieter G H M Raijmakers
Journal:  Eur J Radiol       Date:  2005-10       Impact factor: 3.528

2.  Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer.

Authors:  R Pijpers; S Meijer; O S Hoekstra; G J Collet; E F Comans; R P Boom; P J van Diest; G J Teule
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057

3.  Sentinel lymph node biopsy may be used to support the decision to perform modified radical neck dissection in differentiated thyroid carcinoma.

Authors:  Radan Dzodic; Ivan Markovic; Momcilo Inic; Neven Jokic; Igor Djurisic; Milan Zegarac; Gordana Pupic; Zorka Milovanovic; Viktor Jovic; Nikola Jovanovic
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

4.  Accuracy of sentinel lymph node in papillary thyroid carcinoma.

Authors:  J Arch-Ferrer; D Velázquez; R Fajardo; A Gamboa-Domínguez; M F Herrera
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

5.  Molecular quantification and mapping of lymph-node micrometastases in cervical cancer.

Authors:  P O Van Trappen; V G Gyselman; D G Lowe; A Ryan; D H Oram; P Bosze; A R Weekes; J H Shepherd; S Dorudi; S A Bustin; I J Jacobs
Journal:  Lancet       Date:  2001-01-06       Impact factor: 79.321

6.  The sentinel node procedure with Patent Blue V dye in the surgical treatment of papillary thyroid carcinoma.

Authors:  M R Pelizzo; I M Boschin; A Toniato; P Bernante; A Piotto; A Rinaldo; A Ferlito
Journal:  Acta Otolaryngol       Date:  2001-04       Impact factor: 1.494

7.  Feasibility of sentinel lymph node biopsy and lymphatic mapping in nodular thyroid neoplasms.

Authors:  E Dixon; J G McKinnon; J L Pasieka
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

8.  Sentinel lymph node biopsy in thyroid tumors: a pilot study.

Authors:  Sandro J Stoeckli; Madeleine Pfaltz; Hans Steinert; Stephan Schmid
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-03-18       Impact factor: 2.503

9.  The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy.

Authors:  Rik Pijpers; Marrije R Buist; Arthur van Lingen; Jan Dijkstra; Paul J van Diest; Gerrit J J Teule; Peter Kenemans; René H M Verheijen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-25       Impact factor: 9.236

10.  Thyroid cancer: some basic considerations.

Authors:  H J Wanebo; W Andrews; D L Kaiser
Journal:  Am J Surg       Date:  1981-10       Impact factor: 2.565

View more
  12 in total

1.  Systematic reviews of diagnostic tests in endocrinology: an audit of methods, reporting, and performance.

Authors:  Gabriela Spencer-Bonilla; Naykky Singh Ospina; Rene Rodriguez-Gutierrez; Juan P Brito; Nicole Iñiguez-Ariza; Shrikant Tamhane; Patricia J Erwin; M Hassan Murad; Victor M Montori
Journal:  Endocrine       Date:  2017-06-05       Impact factor: 3.633

2.  Radioguided sentinel lymph node biopsy in patients with papillary thyroid carcinoma.

Authors:  Mattia Portinari; Paolo Carcoforo
Journal:  Gland Surg       Date:  2016-12

3.  SPECT/CT sentinel lymph node identification in papillary thyroid cancer: lymphatic staging and surgical management improvement.

Authors:  Amparo Garcia-Burillo; Isabel Roca Bielsa; Oscar Gonzalez; Carles Zafon; Monica Sabate; Josep Castellvi; Xavier Serres; Carmela Iglesias; Ramon Vilallonga; Enric Caubet; Jose Manuel Fort; Jordi Mesa; Manuel Armengol; Joan Castell-Conesa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-02       Impact factor: 9.236

4.  Diagnostic accuracy of ultrasound, CT and their combination in detecting cervical lymph node metastasis in patients with papillary thyroid cancer: a systematic review and meta-analysis.

Authors:  Jian Yang; Fengyan Zhang; Ying Qiao
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

Review 5.  Sentinel lymph node biopsy in small papillary thyroid cancer. A review on novel surgical techniques.

Authors:  Ludovico Maria Garau; Domenico Rubello; Alice Ferretti; Giuseppe Boni; Duccio Volterrani; Gianpiero Manca
Journal:  Endocrine       Date:  2018-07-02       Impact factor: 3.633

6.  Long-term prognosis of patients with cardiac syndrome X: a review.

Authors:  I A C Vermeltfoort; G J J Teule; A B van Dijk; H J Muntinga; P G H M Raijmakers
Journal:  Neth Heart J       Date:  2012-09       Impact factor: 2.380

7.  The Utility of Sentinel Lymph Node Biopsy in Papillary Thyroid Carcinoma with Occult Lymph Nodes.

Authors:  Xingqiang Yan; Ruichao Zeng; Zhaosheng Ma; Chengze Chen; Endong Chen; Xiaohua Zhang; Feilin Cao
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

8.  One-step nucleic acid amplification analysis of sentinel lymph nodes in papillary thyroid cancer patients.

Authors:  Krzysztof A Kaczka; Lech Pomorski
Journal:  Arch Med Sci       Date:  2017-01-25       Impact factor: 3.318

9.  Regional Node Distribution in Papillary Thyroid Cancer with Microscopic Metastasis.

Authors:  Luis-Mauricio Hurtado-López; Alejandro Ordoñez-Rueda; Felipe-Rafael Zaldivar-Ramírez; Erich Basurto-Kuba
Journal:  J Thyroid Res       Date:  2018-11-01

10.  Sentinel lymph node in thyroid tumors - own experience.

Authors:  Krzysztof Kaczka; Bartłomiej Luks; Jakub Jasion; Lech Pomorski
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.